Share:

Michael E. Goldberg

ScholarGPS® ID: 96702748849056

Affiliation

Foundation Medicine, Inc., United States

Affiliation History

Field

Medicine

Discipline

Oncology

Top Specialties

Cancer

Metrics Summary

Publication Count

9

Predicted Citations

579

Predicted h-index

7

Ranking

Publications and Citation History

Publications based on Top Specialties

Types of Publication

Publications
Books
Patents
NIH/NSF

Add Delete
Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models (journal article) Moore, Heather M. \| Savage, Heidi M. \| O'Brien, Carol \| Zhou, Wei \| Sokol, Ethan S. \| Goldberg, Michael E. \| Metcalfe, Ciara \| Friedman, Lori S. \| Lackner, Mark R. \| Wilson, Timothy R. Molecular Cancer Therapeutics, volume 19, issue 1, pages 292-303 (2020). 10.1158/1535-7163.MCT-19-0284 Cited by (9) \| Cite \| Source
Erratum to “Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib” [Lung Cancer, 108 (June 2017) 228–231] (journal article) Ou, Sai-Hong Ignatius \| Cui, Jean \| Schrock, Alexa B. \| Goldberg, Michael E. \| Zhu, Viola W. \| Albacker, Lee \| Stephens, Philip J. \| Miller, Vincent A. \| Ali, Siraj M. Lung Cancer, volume 138 (2019). 10.1016/j.lungcan.2019.08.013 Cited by (4) \| Cite \| Source
Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies (journal article) Hartmaier, Ryan J. \| Charo, Jehad \| Fabrizio, David \| Goldberg, Michael E. \| Albacker, Lee A. \| Pao, William \| Chmielecki, Juliann Genome Medicine, volume 9, issue 1 (2017). 10.1186/s13073-017-0408-2 Cited by (50) \| Cite \| Source \| Open Access
Analyzing biomarkers of cancer immunotherapy (CIT) response using a real-world clinico-genomic database (journal article) Singal, G. \| Miller, P.G. \| Agarwala, V. \| Li, G. \| Gossai, A. \| Albacker, L.A. \| Goldberg, M.E. \| He, J. \| Frank, S. \| Bourque, D. \| ... \| Stephens, P.J. Annals of Oncology, volume 28, issue suppl_5 (2017). 10.1093/annonc/mdx376.005 Cited by (9) \| Cite \| Source \| Open Access
Immune checkpoint inhibitor (ICPI) efficacy and resistance detected by comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC) (journal article) Ross, J.S. \| Goldberg, M.E. \| Albacker, L.A. \| Gay, L.M. \| Agarwala, V. \| Elvin, J.A. \| Vergilio, J-A. \| Suh, J. \| Ramkissoon, S. \| Severson, E. \| ... \| Stephens, P.J. Annals of Oncology, volume 28, issue suppl_5 (2017). 10.1093/annonc/mdx376.004 Cited by (9) \| Cite \| Source \| Open Access
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib (journal article) Ou, Sai-Hong Ignatius \| Cui, Jean \| Schrock, Alexa B. \| Goldberg, Michael E. \| Zhu, Viola W. \| Albacker, Lee \| Stephens, Philip J. \| Miller, Vincent A. \| Ali, Siraj M. Lung Cancer, volume 108 (2017). 10.1016/j.lungcan.2017.04.003 Cited by (127) \| Cite \| Source \| Open Access
DNA-based genomic profiling for classification of tissue of origin for patients with carcinoma of unknown primary site. (journal article) Albacker, Lee A \| Goldberg, Michael E \| Amler, Lukas C. \| Frampton, Garrett Michael \| Ross, Jeffrey S. \| Suh, James \| Miller, Vincent A. \| Stephens, Phil \| Chmielecki, Juliann Journal of Clinical Oncology, volume 34, issue 15_suppl, pages 11519-11519 (2016). 10.1200/jco.2016.34.15_suppl.11519 Cite \| Source
Analysis of BRAF alterations and molecular profiling in glioblastoma and astrocytoma. (journal article) Faiq, Nadia \| Chmielecki, Juliann \| Goldberg, Michael \| Stephens, Phil \| Kurzrock, Razelle \| Kesari, Santosh \| Piccioni, David Eric Journal of Clinical Oncology, volume 33, issue 15_suppl, pages 2074-2074 (2015). 10.1200/jco.2015.33.15_suppl.2074 Cited by (1) \| Cite \| Source
Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial. (journal article) Burkes, R L \| Ginsberg, R J \| Shepherd, F A \| Blackstein, M E \| Goldberg, M E \| Waters, P F \| Patterson, G A \| Todd, T \| Pearson, F G \| Cooper, J D Journal of Clinical Oncology, volume 10, issue 4, pages 580-586 (1992). 10.1200/JCO.1992.10.4.580 Cited by (184) \| Cite \| Source